Maruyama Koji, Okada Takuya, Ueha Takeshi, Isohashi Kayako, Ikeda Hayato, Kanai Yasukazu, Sasaki Koji, Gentsu Tomoyuki, Ueshima Eisuke, Sofue Keitaro, Nogami Munenobu, Yamaguchi Masato, Sugimoto Koji, Sakai Yoshitada, Hatazawa Jun, Murakami Takamichi
Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Oncol Lett. 2021 Mar;21(3):207. doi: 10.3892/ol.2021.12468. Epub 2021 Jan 14.
Carbon dioxide (CO) treatment is reported to have an antitumor effect owing to the improvement in intratumoral hypoxia. Previous studies were based on histological analysis alone. In the present study, the improvement in intratumoral hypoxia by percutaneous CO treatment was determined using F-fluoromisonidazole positron emission tomography-computed tomography (F-FMISO PET-CT) images. Twelve Japanese nude mice underwent implantation of LM8 tumor cells in the dorsal subcutaneous area 2 weeks before percutaneous CO treatment and F-FMISO PET-CT scans. Immediately after intravenous injection of F-FMISO, CO and room air were administered transcutaneously in the CO-treated group (n=6) and a control group (n=6), respectively; each treatment was performed for 10 minutes. PET-CT was performed 2 h after administration of F-FMISO. F-FMISO tumor uptake was quantitatively evaluated using the maximum standardized uptake value (SUV), tumor-to-liver ratio (TLR), tumor-to-muscle ratio (TMR), metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Mean ± standard error of the mean (SEM) of the tumor volume was not significantly different between the two groups (CO-treated group, 1.178±0.450 cm; control group, 1.368±0.295 cm3; P=0.485). Mean ± SEM of SUV, TLR, MTV (cm3) and TLG were significantly lower in the CO-treated group compared with the control group (0.880±0.095 vs. 1.253±0.071, P=0.015; 1.063±0.147361 vs. 1.455±0.078, P=0.041; 0.353±0.139 vs. 1.569±0.438, P=0.015; 0.182±0.070 vs. 1.028±0.338, P=0.015), respectively. TMR was not significantly different between the two groups (4.520±0.503 vs. 5.504±0.310; P=0.240). In conclusion, F-FMISO PET revealed that percutaneous CO treatment improved intratumoral hypoxia . This technique enables assessment of the therapeutic effect in CO treatment by imaging, and may contribute to its clinical application.
据报道，二氧化碳（CO）治疗由于改善了肿瘤内缺氧情况而具有抗肿瘤作用。以往的研究仅基于组织学分析。在本研究中，使用F-氟代米索硝唑正电子发射断层扫描-计算机断层扫描（F-FMISO PET-CT）图像来确定经皮CO治疗对肿瘤内缺氧的改善情况。12只日本裸鼠在经皮CO治疗和F-FMISO PET-CT扫描前2周，于背部皮下区域植入LM8肿瘤细胞。在静脉注射F-FMISO后，立即分别对CO治疗组（n = 6）和对照组（n = 6）进行经皮给予CO和空气；每次治疗持续10分钟。在给予F-FMISO后2小时进行PET-CT检查。使用最大标准化摄取值（SUV）、肿瘤与肝脏比值（TLR）、肿瘤与肌肉比值（TMR）、代谢肿瘤体积（MTV）和总病变糖酵解（TLG）对F-FMISO在肿瘤中的摄取进行定量评估。两组之间肿瘤体积的平均值±平均标准误差（SEM）无显著差异（CO治疗组，1.178±0.450 cm；对照组，1.368±0.295 cm³；P = 0.485）。与对照组相比，CO治疗组的SUV、TLR、MTV（cm³）和TLG的平均值±SEM显著更低（0.880±0.095对1.253±0.071，P = 0.015；1.063±0.147361对1.455±0.078，P = 0.041；0.353±0.139对1.569±0.438，P = 0.015；0.1十八、2±0.070对1.028±0.338，P = 0.015）。两组之间的TMR无显著差异（4.520±0.503对5.504±0.310；P = 0.240）。总之，F-FMISO PET显示经皮CO治疗改善了肿瘤内缺氧情况。该技术能够通过成像评估CO治疗的疗效，并可能有助于其临床应用。
